Health Economics›Head and neck cancer›Locally advanced disease definitive therapy

Locally advanced disease definitive therapy

Head and neck cancer · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cetuximab and RT Variant #01	—	R 96 465	49d	~22.4 mo	~46.0 mo	~14	~R 1 350 514 PFS proxy · indirect	4
Carboplatin, Fluorouracil, Cetuximab, RT Variant #01	—	R 88 550	49d	~37.9 mo	—	~24	~R 2 125 199 PFS proxy · indirect	1
Fluorouracil, Mitomycin, RT Variant #01	—	R 5 688	56d	—	~23.0 mo	—	—	1
Carboplatin and Paclitaxel (CP) and RT Variant #01	—	R 3 785	35d	—	~18.2 mo	—	—	3
Carboplatin, Fluorouracil, RT Variant #01	—	R 3 616	35d	—	—	—	—	—
Fluorouracil and RT Variant #08	—	R 3 059	77d	—	~33.0 mo	—	—	—
Docetaxel and RT Variant #01	—	R 2 897	49d	—	~25.5 mo	—	—	1
Paclitaxel and RT Variant #01	—	R 2 428	—	—	—	—	—	—
Cisplatin and Fluorouracil (CF) and RT Variant #13	—	R 1 850	28d	—	~16.5 mo	—	—	1
Carboplatin and RT Variant #01	—	R 1 516	42d	—	~22.4 mo	—	—	1
Cisplatin and RT Variant #01	—	R 1 500	49d	—	~58.6 mo	—	—	10
Docetaxel, Fluorouracil, Hydroxyurea, RT Variant #01	—	R 1 159	14d	—	—	—	—	1
Cisplatin, Nimotuzumab, RT Variant #01 Partial	—	R 1 050	49d	—	—	—	—	1
Fluorouracil, Hydroxyurea, RT Variant #01	—	R 663	14d	—	—	—	—	—
Cisplatin and Paclitaxel (TP) and RT N/A - secondary systemic drug	—	R 350	28d	—	—	—	—	1
Bleomycin, Methotrexate, Vinblastine/RT Variant #01	—	R 299	14d	—	—	—	—	—
Radiation therapy N/A - radiation Partial	—	—	49d	—	~29.3 mo	—	—	4

17 of 17 regimens shown